# A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

> **NCT01072149** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- **DEVICE:** placebo

## Key facts

- **NCT ID:** NCT01072149
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-01
- **Primary completion:** 2010-07-01
- **Final completion:** 2010-07-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072149, "A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01072149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*